Search
CytomX Therapeutics Inc
CTMXAdd to Watchlist
2.760USD
-0.060-2.13%
Close 09-18 16:00（ET）
599.22MMarket Cap
LossP/E TTM
After-hours 19:09 (ET)2.730USD-0.025-0.91%
After-hours 19:09 (ET)CytomX Therapeutics Inc (CTMX) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to CytomX Therapeutics Inc in the past month.
Strong Buy
4 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
12.429USD+362.03%
CTMX Analyst Recommendation Trends
In the current month, CTMX has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CTMX average Analyst price target in the last month is 12.429.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
5
4
4
4
4
4
4
4
4
5
5
4
4
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
9
9
9
9
9
CTMX Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, CTMX EPS is projected to reach -0.087 in FY2026Q3, following reported EPS of -0.094 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.09
-0.12
-0.08
-0.09
-0.10
Actual
-0.17
-0.10
-0.09
--
--
Surprise
-85.67%
+14.77%
-21.79%
--
--
FAQs
What is CytomX Therapeutics Inc's expected revenue for the next quarter?
CytomX Therapeutics Inc's expected revenue is 5.00M.
What is CytomX Therapeutics Inc's price target?
Analysts forecast that CytomX Therapeutics Inc's price target is USD 12.43, with the highest forecast at USD 16.00 and the lowest forecast at USD 6.00.
How have CytomX Therapeutics IncCTMX's recent earnings per share performed?
The market expectation was USD -0.09, while CytomX Therapeutics IncCTMX's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for CytomX Therapeutics Inc?
Based on the ratings of CytomX Therapeutics Inc's stock from 8 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.